Roche Says Phase 3 Studies for Alzheimer's Drug Failed to Meet Primary Endpoints
November 14 2022 - 2:06AM
Dow Jones News
By Pierre Bertrand
Roche Holding AG said Monday that Phase 3 Graduate studies of
gantenerumab, for treatment of early Alzheimer's disease, failed to
meet its primary endpoints.
The Swiss pharma company said the drug failed to slow patients'
clinical decline and that the drug's removal of beta-amyloid, a
protein that builds up to make plaques in the brains of people with
Alzheimer's disease, was lower than expected.
The company said it would keep working on novel diagnostics and
treatments for Alzheimer's and said it would present at the
Clinical Trials on Alzheimer's Disease Conference.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
(END) Dow Jones Newswires
November 14, 2022 01:51 ET (06:51 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2024 to May 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From May 2023 to May 2024
